Cubist buy rating reiterated by Merrill

Merrill Lynch reiterated its buy rating for Cubist Pharmaceutical Inc. Analyst David Muno predicted that data from the phase-three clinical trial of drug Cubicin to be presented in December will be positive and that sales of the drug could peak at $350 to $450 million. He therefore advised investors to focus on sales growth and label expansion in 2006.

Shares of the Lexington, Mass.-based pharmaceutical company were up $0.27, or 1.57%, at $17.47 on volume of 1,061,574 shares versus the three-month running average of 743,985 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.